Novelmed Therapeutics
Manufacturing · Ohio, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11000 Cedar Ave Ste 135, Cleveland, Ohio...Phone Number
(216) 707-1776Website
www.novelmed.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Novelmed Therapeutics
NovelMed is a biotechnology company focused on developing innovative therapies for rare diseases, particularly those mediated by the complement system. They have a promising pipeline of antibody therapies, including NM5072 and NM8074, which have shown positive results in clinical trials for conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD). The company aims to lead the rare disease market with its unique mechanism of action and strong intellectual property. NovelMed is actively seeking partnerships and investments to further advance its research and development efforts.Explore more
Novelmed Therapeutics Org Chart
YG
Regulatory Affairs Associate
TS
Research Scientist
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Novelmed Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Novelmed Therapeutics has new funding data
Novelmed Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Novelmed Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Novelmed Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Novelmed Therapeutics had a recent Job posting/layoffs
Check out if Novelmed Therapeutics is spiking on competitors!
Product Launch: Get notified when Novelmed Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Novelmed Therapeutics
Recommended Actions
Find VP level buyers at Novelmed Therapeutics
Find 2 more new buyers
Compare Similar Companies to Novelmed Therapeutics
Compare insights from companies similar to Novelmed Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Novelmed Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Novelmed Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Novelmed Therapeutics.
Novelmed Therapeutics financials insights
Gather financial insights about Novelmed Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$20K
Novelmed Therapeutics Tech Stack
A closer look at the technologies used by Novelmed Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Novelmed Therapeutics News & Media
NovelMed Advances Its Ocular Program, Highlighting the Potential of a Single Therapy Across Multiple Retinal Diseases
--- A Versatile Complement Therapy Across Ocular, Hematologic, Renal, Dermatological, and Inflammatory Disorders.NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH
--- Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous AdministrationNovelMed’s Phase II Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH).Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Novelmed Therapeutics
Sign Up For FreeTo access detailed company insights
NovelMed is a biotechnology company focused on developing innovative therapies for rare diseases, particularly those mediated by the complement system. They have a promising pipeline of antibody therapies, including NM5072 and NM8074, which have shown positive results in clinical trials for conditions such as paroxysmal nocturnal hemoglobinuria (PN... Read More
